These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 22516345

  • 1. Involvement of signaling molecules in the prediction of response to imatinib treatment in metastatic GIST patients.
    Valadão M, Braggio D, Santos AF, Pimenta-Inada HK, Linhares E, Gonçalves R, Romano S, Vilhena B, Small I, Cubero D, Cruz F, Oliveira AT, Martinho O, Reis RM, Guimarães DP, Ferreira CG.
    J Surg Res; 2012 Nov; 178(1):288-93. PubMed ID: 22516345
    [Abstract] [Full Text] [Related]

  • 2. The lack of CD34 expression in gastrointestinal stromal tumors is related to cystic degeneration following imatinib use.
    Koh Y, Lee HE, Oh DY, Kim JH, Lee SH, Kim SH, Kim DW, Im SA, Kim TY, Heo DS, Kim WH, Bang YJ.
    Jpn J Clin Oncol; 2012 Nov; 42(11):1020-7. PubMed ID: 22952296
    [Abstract] [Full Text] [Related]

  • 3. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
    Yeh CN, Chen TW, Lee HL, Liu YY, Chao TC, Hwang TL, Jan YY, Chen MF.
    Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905
    [Abstract] [Full Text] [Related]

  • 4. Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study.
    Kang HJ, Ryu MH, Kim KM, Park YS, Choi J, Ryoo BY, Kim WH, Im SA, Bang YJ, Park SH, Lee JH, Chung IJ, Bae HI, Kim JG, Lee KH, Song HS, Kwon HC, Baek JH, Shin DB, Lee KE, Kang YK.
    Acta Oncol; 2012 Apr; 51(4):528-36. PubMed ID: 22150077
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
    Demetri GD.
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment.
    Yeh CN, Chen TW, Tseng JH, Liu YY, Wang SY, Tsai CY, Chiang KC, Hwang TL, Jan YY, Chen MF.
    J Surg Oncol; 2010 Nov 01; 102(6):599-603. PubMed ID: 20976730
    [Abstract] [Full Text] [Related]

  • 9. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.
    Mussi C, Schildhaus HU, Gronchi A, Wardelmann E, Hohenberger P.
    Clin Cancer Res; 2008 Jul 15; 14(14):4550-5. PubMed ID: 18628470
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
    Rutkowski P, Debiec-Rychter M, Nowecki ZI, Wozniak A, Michej W, Limon J, Siedlecki JA, Jerzak Vel Dobosz A, Grzesiakowska U, Nasierowska-Guttmejer A, Sygut J, Nyckowski P, Krawczyk M, Ruka W.
    Med Sci Monit; 2007 Nov 15; 13(11):CR515-522. PubMed ID: 17968300
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Molecular and genetic features of gastrointestinal stromal tumors (GIST)].
    Buleje S J, Yábar B A, Guevara-Fujita M, Fujita R.
    Rev Gastroenterol Peru; 2012 Nov 15; 32(4):394-9. PubMed ID: 23307090
    [Abstract] [Full Text] [Related]

  • 17. [Study on the mechanism of imatinib-induced resistance in gastrointestinal stromal tumors].
    Zhou Y, Hou YY, Tan YS, Lu SH, Hou J, Liu JL, Qin J, Shen KT, Sun YH.
    Zhonghua Zhong Liu Za Zhi; 2009 Aug 15; 31(8):597-601. PubMed ID: 20021947
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
    Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H.
    N Engl J Med; 2002 Aug 15; 347(7):472-80. PubMed ID: 12181401
    [Abstract] [Full Text] [Related]

  • 19. Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.
    Kang YK, Kang BW, Im SA, Lee JL, Park SR, Kang WK, Chang HM, Kim TW, Oh DY, Jung KH, Ryu MH.
    Cancer Chemother Pharmacol; 2013 Jan 15; 71(1):43-51. PubMed ID: 23053257
    [Abstract] [Full Text] [Related]

  • 20. Kinase mutations and efficacy of imatinib in Korean patients with advanced gastrointestinal stromal tumors.
    Kim TW, Ryu MH, Lee H, Sym SJ, Lee JL, Chang HM, Park YS, Lee KH, Kang WK, Shin DB, Bang YJ, Lee JS, Kang YK.
    Oncologist; 2009 May 15; 14(5):540-7. PubMed ID: 19411681
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.